Becton, Dickinson and Company (NYSE:BDX) Given New $175.00 Price Target at JPMorgan Chase & Co.

Becton, Dickinson and Company (NYSE:BDX) had its price target lowered by JPMorgan Chase & Co. from $190.00 to $175.00 in a report issued on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a neutral rating on the medical instruments supplier’s stock.

Other equities analysts also recently issued research reports about the stock. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Barclays started coverage on Becton, Dickinson and Company in a research report on Tuesday. They issued an “overweight” rating and a $202.00 price objective for the company. Jefferies Financial Group boosted their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Wells Fargo & Company lowered their target price on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $196.00.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $171.55 on Tuesday. The stock’s 50 day moving average is $199.76 and its 200 day moving average is $192.43. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $235.34. The firm has a market cap of $48.88 billion, a P/E ratio of 27.99, a P/E/G ratio of 2.72 and a beta of 0.25. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has approved a stock repurchase program on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 2,463 shares of company stock valued at $501,530. Corporate insiders own 0.40% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

Several institutional investors and hedge funds have recently modified their holdings of the stock. SOA Wealth Advisors LLC. boosted its position in shares of Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 95 shares during the last quarter. Activest Wealth Management lifted its stake in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares in the last quarter. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company during the 3rd quarter worth $25,000. Steph & Co. boosted its holdings in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the last quarter. Finally, Bell Investment Advisors Inc grew its stake in shares of Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 128 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q1 results beat consensus — adjusted EPS $2.91 vs. $2.81 expected and revenue $5.25B vs. $5.15B, showing organic revenue stability and margin improvement that would normally support the stock. BD Reports First Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Company announced up to $1.6B in cash tender offers to repurchase certain outstanding debt — a signal of active balance‑sheet management that can reduce leverage and interest burden. Tender Offers for Outstanding Debt Securities
• Positive Sentiment: Barclays initiated coverage with an Overweight and $202 PT — a notable constructive analyst call amid mixed revisions. Barclays Overweight Initiation
• Neutral Sentiment: Spin-off/combination with Waters completed — a structural change that reduces BD’s scale and alters its earnings base; investors are re‑valuing the “New BD” through guidance and cash deployment plans. Spin-off/Combination Announcement
• Neutral Sentiment: Insiders placed bullish option bets (reported) — a small positive signal of insider confidence but not large enough to move fundamentals alone. Insider Option Activity
• Negative Sentiment: Company cut FY26 adjusted EPS guidance to $12.35–$12.65, well below consensus (~$14.8) — the guidance reset (reflecting the divestiture) is the primary negative driver pushing the stock lower as investors adjust earnings models. Profit Forecast Cut
• Negative Sentiment: Multiple broker price‑target cuts and rating adjustments (JPMorgan, Wells Fargo, Jefferies, RBC and others) compress sentiment — several firms lowered PTs or shifted to neutral/equal‑weight, increasing selling pressure. Analyst Price Target Moves
• Negative Sentiment: Company flagged a reduced profit outlook tied to the sale/combination of its biosciences & diagnostics unit — the near‑term EPS hit and uncertainty around cash deployment timing weigh on valuation. Sale‑Related Profit Outlook

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.